Overview of Butomidor

Quick Facts: Butomidor Overview

Property	Description
Active ingredient	Butorfanol (Butorfanol tartrate)
Form	Solution for injection (parenteral)
Pharmacological class	Opioid analgesic / Agonist-Antagonist
Target Audience	Veterinary (Dogs, Cats, and Horses)
Origin	Synthetic (phenanthrene series)
Manufacturer	Richter Pharma (Austria)

What Type of Medicine is Butomidor?

Butomidor is a brand name for a potent synthetic narcotic analgesic whose active ingredient is Butorfanol, often administered as the tartrate salt. It belongs to the pharmacological class of opioid analgesics. Unlike many comparable pain management substances, Butomidor is primarily recognized as a veterinary medicinal product used in species including dogs, cats, and horses. Butorfanol itself is derived from the phenanthrene series. The compound functions as an opioid receptor agonist-antagonist, which dictates its specific mechanism of action.

Butorfanol: Active Ingredient and Preparation Form

The preparation utilizes Butorfanol as a single active substance, dissolved in an aqueous solution to create a sterile solution for injection. This is the primary suitable form for this medication because Butorfanol is extensively metabolized when administered orally. The injectable form, typically supplied in ampoules, is necessary for parenteral administration to ensure the drug bypasses first-pass metabolism and achieves rapid and reliable systemic delivery. This fast delivery is utilized for managing acute discomfort in clinical settings.

General Purpose: What is the Main Benefit of Butomidor?

The general purpose of this medication is to deliver powerful and rapid relief from intense, acute discomfort. The analgesic effect is achieved because Butorfanol works centrally on the nervous system, directly modulating the pathways that transmit and perceive pain. The drug’s unique agonist-antagonist action provides its characteristic analgesic profile for the short-term management of moderate-to-severe pain, enabling the effective interruption of the patient's sensation of suffering.

What side effects are possible with Butomidor?

Possible Side Effects and Safety Information

The safety profile of Butomidor (Butorphanol) is defined by official regulatory documentation, which classifies adverse reactions based on frequency and affected physiological systems. The most frequent reactions involve the nervous system.

Frequency-Classified Adverse Reactions

The following effects are classified according to regulatory frequency standards:

Classification	Examples of Reactions
Very Common	Sedation, Ataxia (loss of full control of bodily movements, specifically in dogs)
Common	Transient pain at the injection site
Uncommon	Changes in heart rate (bradycardia or tachycardia), Changes in respiratory rate (depression or hyperventilation)
Rare	Excitement or restlessness (observed in cats), Defecation

Documented Safety Considerations

The official label documents that serious adverse reactions, particularly respiratory depression, are a potential consequence of opioid use and are noted as uncommon. Effects involving the cardiac system are also officially classified as uncommon concerns.

Safety constraints restrict the use of Butomidor in certain contexts. The medicine is not recommended for use in individuals with documented severe hepatic impairment, severe renal impairment, or severe cardiac dysfunction. Furthermore, use is advised against in animals presenting with a head injury due to the potential for increased intracranial pressure. Certain population-specific patterns are observed, such as the tendency for cats to exhibit excitement/restlessness (a rare effect) and for horses to show a transient decrease in locomotor activity. Safety may also be affected by the co-administration of other central nervous system (CNS) depressant drugs.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Butorfanol is a severe medical emergency that necessitates immediate intervention. Emergency medical help must be sought immediately if an overdose is suspected, especially upon observing signs of severe central nervous system (CNS) or respiratory distress.

The principal manifestation documented in regulatory sources is respiratory depression, presenting as hypoventilation or shallow breathing. This condition can quickly progress to apnea and potentially respiratory arrest. Other officially listed signs include profound stupor, confusion, coma, and pinpoint pupils (miosis). This severe toxicity carries an official risk of cardiovascular collapse and death.

The mandated treatment procedures detailed in official labeling are focused on supportive and symptomatic care. The specific antagonist for reversing the effects of Butorfanol overdose is documented as Naloxone. Treatment requires establishing a clear airway and ensuring adequate ventilation, potentially through mechanical support, along with continuous monitoring of vital signs. Intravenous fluids and vasopressors are indicated for managing documented circulatory depression.

A consideration noted in official documents is that patients with hepatic impairment may experience a significantly prolonged duration of the drug’s effects due to extended half-life, requiring specialized observation. Furthermore, accidental exposure, particularly in children, carries a high risk of fatal respiratory depression.

Therapeutic Uses of Butomidor

What Butomidor Treats: Main Uses and Benefits

Butomidor is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed, particularly for acute, moderate to severe pain. This is used in accordance with established therapeutic guidelines, and typically includes pain associated with surgical or traumatic episodes. The therapeutic benefit provides support that helps ease the overall symptom burden during episodes of heightened symptoms, contributes to improved comfort during symptomatic periods.

The medication plays a role in managing symptoms linked to organ-specific functional stress. It is considered relevant for easing profound spasmodic abdominal discomfort, such as that seen in horses with colic, and is applied in addressing the persistent, non-productive cough in dogs. This use is relevant for easing agitation and anxiety often driven by pain or the need for clinical handling, assisting with maintaining comfort and supporting patients during episodes of heightened discomfort by easing distress during necessary medical procedures.

“This medication is primarily relevant in contexts marked by increased discomfort or tension, where short-term symptom management is appropriate.”

Quick Fact: Symptomatic Domains of Use
Relevant for	Acute, Moderate to Severe Pain
Supportive Relief	For Agitation and Distress during procedures
Symptom Load	Supports Easing Overall Symptom Load

Regulatory References

UK Veterinary Medicines Directorate Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility and Contraindications

Butomidor is restricted to the target species of horses, dogs, and cats. Eligibility for its use is defined by specific contraindications and use restrictions detailed in official regulatory documents.

Absolute Contraindications

The medicine is prohibited in animals with known hypersensitivity to the active substance or excipients. Contraindications include severe dysfunction of the liver and kidneys, heart dysfunction, cerebral injury, organic brain lesions, or pre-existing obstructive respiratory diseases. Use in dogs afflicted with heartworm disease is also considered unestablished and contraindicated in some regions.

Age and Reproductive Status

Safety has not been established in puppies, kittens, and foals; use in these young animals is restricted and requires a formal risk-benefit analysis. The product is not recommended for use in target species during pregnancy and lactation as safety in these physiological states is unestablished in the official labeling.

Conditional Restrictions

Animals with respiratory diseases associated with increased mucous production must only receive the medicine following a veterinarian’s risk-benefit evaluation. Furthermore, specific combination-use restrictions apply to horses with pre-existing cardiac dysrhythmia or colic associated with impaction.

What should I know about interactions with other medicines?

The official regulatory profile for Butomidor (Butorphanol) documents specific patterns of interaction based on pharmacodynamic and pharmacokinetic principles.

Co-administration with Central Nervous System (CNS) depressants, including sedatives, tranquilizers, anesthetics, and alcohol, carries a high risk due to additive pharmacologic effects that can increase sedation and respiratory depression. The simultaneous use of Butomidor with other Serotonergic Drugs also carries a documented risk of Serotonin Syndrome.

A critical functional restriction involves Pure mu-Opioid Agonists (e.g., Morphine), as Butomidor’s antagonist property at the mu-receptor can actively remove or reverse their analgesic effect. For procedural sedation, Alpha-2-Adrenoceptor Agonists (e.g., Detomidine) produce synergistic effects, necessitating dose adjustments and the adherence to specific timing rules for administration. The product must not be mixed with other medicinal products in the same syringe, constituting an official physical constraint.

Regarding clearance, use is contraindicated in cases of severe liver or kidney dysfunction because the active substance's elimination half-life is significantly tripled in hepatic impairment, leading to greater systemic exposure. Additionally, regulatory documents note that Butomidor should not be used with expectorants to avoid the accumulation of mucous, and co-administration with CYP 450 inhibitors or inducers may require dose adjustment.

Mechanism of Action

Targeting Kappa Opioid Receptors for Nociceptive Modulation

Butomidor's pharmacodynamic mechanism involves dual activity on opioid receptor systems within the Central Nervous System (CNS). A core action is its function as an agonist (activator) at the Kappa Opioid Receptor (kappa-OR). Activation of the kappa-OR initiates a G-protein-coupled signaling cascade that inhibits the release of neurotransmitters essential for carrying nociceptive (pain) signals in the spinal cord and brain. This action contributes to a diminished transmission of nociceptive signals.

Partial Interaction and Systemic Modulation

The compound also engages the Mu Opioid Receptor (mu-OR), where it acts as a partial agonist or antagonist. This interaction results in modulation of central mu-OR activity that defines a specific pharmacological profile, distinguishing its systemic effects from full mu-OR agonists. Furthermore, the mechanism involves a direct influence on the respiratory regulatory centers in the brainstem, altering the control circuits. This leads to an alteration of respiratory rate and depth, achieved by decreasing the central sensitivity to carbon dioxide levels.

Dosage and Administration Information

How Butomidor is Used

Butomidor is administered exclusively through parenteral routes (injection) as a sterile solution. The method varies by target species: horses are restricted to intravenous (IV) use; dogs may receive the drug intravenously (IV), intramuscularly (IM), or subcutaneously (SC); and cats are approved for IV or SC administration.

The standard administration is strictly weight-based, with dosages calculated per kilogram of body mass (mg/kg). For instance, the monotherapy regimen for horses is 0.1 mg/kg IV. Dogs are typically administered between 0.1 and 0.4 mg/kg, while cats are dosed at 0.4 mg/kg for SC injection or 0.1 mg/kg for IV injection.

Usage follows an intermittent, short-term schedule. The drug is not intended for continuous use. Repeat administration is authorized after a defined interval, which is typically three to four hours, depending on the species. For horses, treatment duration typically does not exceed 48 hours.

Procedural constraints govern proper administration. Rapid intravenous injection must be avoided and the solution should be administered slowly when using this route. Furthermore, the solution must not be mixed with any other medicinal products in the same syringe for preparation. While dosing is primarily weight-based, the safety of the drug in very young patients, such as foals, puppies, and kittens, requires assessment prior to use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Butomidor

Evidence for Acute, Moderate-to-Severe Discomfort (Analgesia)

Research examining outcomes related to physical discomfort was evaluated in studies focusing on conditions associated with acute or disruptive episodes, such as those following soft tissue surgery or trauma. These investigations utilized Randomized Controlled Trials (RCTs) and controlled crossover designs. Studies were conducted during periods of increased symptom activity in dogs and cats, as well as horses following major abdominal surgery. Researchers measured outcomes related to the intensity of discomfort, changes in pain threshold in models, and monitored the level of physiological strain by tracking stress hormone levels.

Studies focused on research exploring short-term symptom changes, with the primary patterns typically observed over a limited duration—generally measured between three and six hours following the intervention. Findings from some comparative trials indicate that patterns related to measured outcomes were observed to differ when this medicine was evaluated against alternative pharmacological approaches for specific procedures. The available research provides limited insight into the durability of the observed changes, as the follow-up durations were primarily limited to short-term assessment.

Evidence for Acute Abdominal Discomfort and Colic (Horses)

The evidence base for this medicine's use in conditions involving periods of heightened symptoms, specifically acute abdominal discomfort in horses (colic), primarily relies on Clinical Field Trials and some Randomized Controlled Trials. Research monitored observable Abdominal Pain Signs (specific behaviors like rolling or flank-watching) and recorded the time interval until the pattern of discomfort was noted to change. Data show patterns related to how pain behaviors evolved in the observed populations during the defined time intervals. Additionally, research focusing on abdominal surgery patients observed a change in a specific functional outcome: the measured time taken for the patient to pass feces for the first time post-operation.

What is Still Uncertain About the Research for Butomidor

Comparative evidence is lacking in several areas, particularly for its use in cough relief and in head-to-head assessments against newer alternative pharmacological approaches. Furthermore, long-term effects are not fully established, as most studies focused on immediate, acute outcomes. Research does not determine whether an individual will respond similarly, and findings describe group patterns, not personal outcomes.

Key Studies & References Butomidor 10 mg/ml solution for injection: Summary of Product Characteristics (SPC) - UK Veterinary Medicines Directorate

Frequently Asked Questions (FAQ)

Common questions about Butomidor (FAQ)

Q: What is the main difference between Butomidor and [similar popular drug]?

A: Official documents describe Butomidor (Butorphanol) as an opioid agonist-antagonist. This means it activates the kappa receptor while acting as a partial agonist or antagonist at the mu receptor. The mechanism of action is defined by this dual activity, which sets it apart from opioid medicines that are categorized as pure mu-opioid agonists.

Q: Is Butomidor considered a controlled substance?

A: According to regulatory agencies, Butomidor (Butorphanol) is officially designated as a Controlled Substance in many regions, such as a Schedule IV substance in the United States. This classification indicates that specific regulatory controls are mandated for its handling, prescribing, and use.

Q: How quickly does Butomidor start working after I take it?

A: Regulatory information indicates that the onset of the intended effect is typically observed within minutes following intravenous (IV) injection. This timing is a factor in its intended use for managing acute discomfort.

Q: Can Butomidor affect your mood or mental state?

A: Official documentation notes that Butomidor acts on the central nervous system (CNS). This can lead to effects such as sedation (drowsiness) and, in specific species, rare patterns of excitement or restlessness. These reactions are officially documented as involving changes to the normal mental or nervous system state.

Q: Are there any known food or drink interactions with Butomidor?

A: Official documents specifically list potential risks associated with the co-administration of Butomidor with alcohol and other central nervous system (CNS) depressants. However, the regulatory information does not specify any known interactions with general food intake.

Q: Is Butomidor a habit-forming medicine?

A: Because Butomidor is classified as a Controlled Substance in the opioid analgesic class, regulatory bodies implicitly acknowledge the potential for dependence. This classification mandates specific controls on its distribution and use to mitigate potential risks.

Q: Can older adults safely use Butomidor?

A: Official documents emphasize that use should always be guided by a formal risk-benefit assessment in all patient populations. This is particularly important in populations like older adults where safety may not have been fully established in all product labels.

Q: Does Butomidor interact with herbal supplements like St. John's Wort?

A: The official label contains warnings for co-administration with other Serotonergic Drugs and with medicines that affect CYP 450 enzymes. These general interaction categories may apply to certain herbal supplements, which is why official sources note that co-administration may require adjustment.

Q: What should I do if a side effect seems severe?

A: Official guidelines require healthcare professionals to report all serious adverse reactions. Regulatory information indicates that, as with any serious opioid effect, prompt professional attention is required if severe reactions are observed, such as severe respiratory depression.

Q: Is there a generic version of Butomidor available?

A: The availability of generic alternatives containing Butorphanol is determined by regulatory authorization and can be verified by reviewing the official list of approved drug products.

Q: Does Butomidor affect sleep patterns?

A: According to official product information, a very common adverse reaction documented is sedation (drowsiness). This central nervous system effect can naturally influence resting and sleep states, as noted in the safety profile.

Q: What makes Butomidor different from older medicines used for the same thing?

A: Regulatory documents define Butomidor by its unique mechanism: it is an opioid agonist-antagonist. This means it is designed to activate the kappa receptor while simultaneously exerting a partial or antagonistic effect at the mu receptor. This mechanism sets it apart from pure mu agonists.

Q: What's the official safety classification of Butomidor in major countries?

A: Butomidor (Butorphanol) is officially classified as an opioid analgesic and is listed as a Schedule IV Controlled Substance in many regulatory systems. This classification reflects its pharmacological class and mandates legal controls over its use.

Q: Does Butomidor have a risk of withdrawal symptoms when stopping it?

A: Regulatory warnings about the potential for dependence are present due to its opioid analgesic status. Additionally, the label addresses the risk of reversing the effects of pure mu agonists. These regulatory notes underscore the importance of professional oversight when stopping use.

Q: Can Butomidor interact with common cold or allergy medicines?

A: The official label documents a high risk of additive effects when Butomidor is co-administered with Central Nervous System (CNS) depressants. This class of drugs includes components found in many common cold and allergy medicines, which can potentially increase sedation.

Q: Is Butomidor only available by prescription?

A: Official documents explicitly state that Butomidor is a Prescription Only Medicine (POM) or is subject to equivalent restrictive dispensing requirements. Therefore, the medication is not legally available for sale or dispensing without a valid prescription.

Q: How long does Butomidor stay in your system after you stop taking it?

A: The label provides pharmacokinetic data including the elimination half-life of the active substance. This half-life measure is used to estimate the time it takes for the drug concentration in the body to be significantly reduced after administration stops.

Q: What are the main ingredients in Butomidor?

A: The official regulatory label identifies the active ingredient, Butorphanol tartrate, which is responsible for the drug’s effects. The label also lists the various excipients (inactive ingredients) used to create the sterile solution for injection.

Q: Why does Butomidor have to be taken exactly as prescribed?

A: The official regulatory documents mandate strict adherence to administration procedures, such as slow intravenous injection and weight-based dosing. These rules are in place due to the potential for serious adverse reactions, particularly respiratory depression, if the drug is not administered correctly.

Q: What does the official label say about overdose with Butomidor?

A: The official label includes specific information describing the symptoms associated with overdose, such as severe respiratory depression. Furthermore, regulatory documents specify the recommended antidotes or treatments to be used in the event of an overdose.

How should Butomidor be stored and disposed of?

How to Store and Dispose of Butomidor

The storage and disposal of Butomidor (Butorphanol tartrate solution for injection) must strictly follow the official instructions documented in the regulatory label.

Storage Conditions

Condition	Requirement
Temperature	Store below 25°C.
Light/Container	Protect from light by keeping the vial in its outer box.
Prohibited Storage	Do not store in the refrigerator or freezer.
Child Safety	Keep out of the sight and reach of children.
Stability	Shelf life after first opening the vial is 28 days.

Handling and Disposal

Care must be taken during handling to avoid accidental injection, as Butorphanol has opioid-like activity in humans. Any unused product or waste material must be disposed of in accordance with local requirements to ensure the medication is handled and discarded safely under regional protocols.

Butomidor